Research & Sourcing Policy

RESEARCH • SOURCES • EVIDENCE HIERARCHY

Research & Sourcing Policy

Melanotan.info uses an evidence hierarchy so that a controlled human trial, an FDA label, a case report and a social-media anecdote are not presented as though they prove the same thing.

Our source hierarchy

  1. Peer-reviewed human research, especially controlled clinical studies.
  2. Official regulatory and prescribing sources from agencies such as FDA, MHRA, TGA and Health Canada.
  3. Peer-reviewed reviews and mechanistic research that help explain biology and place individual studies in context.
  4. Observational evidence and case reports, which can identify patterns or safety signals but may not prove causation.
  5. Anecdotal reports, which may help identify questions but are not treated as clinical evidence.

Primary sources are preferred

When a claim can be supported by the underlying clinical paper, prescribing label or regulator guidance, we prefer that source over a news article, commercial summary or secondary blog.

Secondary sources may be useful for context, but important medical or regulatory conclusions should be traceable to stronger underlying evidence whenever reasonably possible.

How we handle Melanotan I, afamelanotide and MT2

Research involving these compounds is not automatically merged. Afamelanotide data may be relevant to melanocortin biology and pigmentary effects, but the regulated SCENESSE product should not be treated as proof that an unrelated product labeled “MT1” has the same formulation, quality or safety.

Similarly, MT2 findings are attributed to MT2 when the research actually studied MT2 rather than generalized to every melanotan product.

How we use case reports

Case reports can be valuable early warnings, especially for rare events. But they generally cannot determine how often an event occurs, eliminate confounding variables or prove that the exposure caused the outcome.

When discussing melanoma, priapism or another serious event reported after melanotan exposure, we aim to state both the signal and the limitation.

How we use regulatory sources

Regulatory claims can change with new guidance, enforcement, labeling or legislation. Country-specific legal and regulatory pages should rely on current official sources and avoid presenting one jurisdiction’s rules as universal.

Where the legal answer depends on the specific product, intended use or activity, we say so rather than forcing a simplistic yes-or-no conclusion.

Anecdotes and user submissions

User experiences and before-and-after photographs can illustrate real-world questions, but they are not substitutes for clinical evidence. If such content is published, it should be labeled as user-submitted or anecdotal and should not be described as medically verified unless verification actually occurred.

Images should only be used when publication rights are clear. Relevant context—such as timeframe, known compound, UV exposure or editing—should be included when available.

What we avoid

  • citing seller claims as proof of efficacy or purity
  • using the number of forum reports as an incidence estimate
  • treating animal or laboratory findings as established human outcomes
  • presenting a mechanism as proof of a clinical benefit
  • using case reports to claim proven causation
  • claiming a source supports more than it actually states

Source updates

If an official label, regulator statement or higher-quality study supersedes an older source, the page should be reviewed and updated where the change materially affects the conclusion.

Scroll to Top